Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Sionna Therapeutics, Inc. (SION)

$45.70 +3.72% NASDAQ: SION · 15-min delayed
  • WALTHAM, Massachusetts
  • Public · NASDAQ: SION
  • 59 employees
$1.6BMarket cap
-$75.3MNet income
59Employees
SIONNASDAQ
2025IPO

About Sionna Therapeutics, Inc.

Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Net income
-$75.3M
Total assets
$326.0M
Market cap
$1.6B

Source: SEC EDGAR · updated Jun 7, 2026

FY 2025

Financial statements

Income statement

Revenue
$0
Operating expenses
$89.0M
Operating income
-$89.0M
Income tax
$0
Net income
-$75.3M
EPS (basic)
$-1.88
EPS (diluted)
$-1.88

Balance sheet

Total assets
$326.0M
Current assets
$241.4M
Total liabilities
$19.1M
Current liabilities
$11.7M
Shareholders’ equity
$306.8M

Cash flow

Operating cash flow
-$66.3M
Investing cash flow
-$118.7M
Financing cash flow
$205.7M
Net cash flow
$20.7M

Statements via Polygon.io (SEC filings)

NASDAQ: SION
$45.70 +3.72%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$14.10 $49.41

52-week range

Market cap
$1.6B
EPS (diluted)
$-1.88
Shares outstanding
34.9M
Open
Day range
Prev close
Volume
IPO date
Feb 7, 2025

Sionna Therapeutics, Inc. (SION) Stock Price

  • Reported a net loss of $75.3M.
  • Trading 8% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Sionna Therapeutics, Inc..

Write a review
Newsroom

News about Sionna Therapeutics, Inc.

News & sentiment via Polygon.io

FAQ

Sionna Therapeutics, Inc.: frequently asked questions

Is Sionna Therapeutics, Inc. an American company?

Sionna Therapeutics, Inc. is a US-based company headquartered in Waltham, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Sionna Therapeutics, Inc. headquartered?

Sionna Therapeutics, Inc. is headquartered in Waltham, Massachusetts, United States.

Is Sionna Therapeutics, Inc. publicly traded?

Yes — Sionna Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol SION on the NASDAQ.

What does Sionna Therapeutics, Inc. do?

Sionna Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →